The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Christiane E. Angermann et al.|Nature Medicine|2022Cited by 889
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Robert Gordon et al.|Nature Medicine|2021Cited by 599
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection FractionMichael E. Nassif, John M. Cox, Sheryl L. Windsor et al.|Circulation|2019Cited by 427
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213